Payment overview · 2025
General Payments
$251.30
11 reported records · 5 companies
Healthcare provider profile · identity verified
Leonel L Rodriguez, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLYTHE, CA · NPI 1912098872
Verified facts
What the public records show
CMS Open Payments records show Leonel L Rodriguez, MD received $251.30 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $160.37 | 63.8% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $29.51 | 11.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.74 | 9.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.60 | 8.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.08 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $251.30 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $160.37 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.30 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 264 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 217 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
264 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 609 | 74 |
| Gabapentin | Gabapentin | 489 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 111 |
| Metformin Hcl | Metformin Hcl | 427 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 419 | 102 |
| Omeprazole | Omeprazole | 398 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 368 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 290 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 57 |
| Ibuprofen | Ibuprofen | 265 | 67 |
| Eliquis | Apixaban | 264 | 45 |
| Lisinopril | Lisinopril | 255 | 63 |
| Ramipril | Ramipril | 240 | 55 |
| Furosemide | Furosemide | 238 | 49 |
| Trazodone Hcl | Trazodone Hcl | 234 | 47 |
| Farxiga | Dapagliflozin Propanediol | 217 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 212 | 24 |
| Montelukast Sodium | Montelukast Sodium | 207 | 37 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 202 | 44 |
| Meloxicam | Meloxicam | 200 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 179 | 42 |
| Potassium Chloride | Potassium Chloride | 174 | 27 |
| Benazepril Hcl | Benazepril Hcl | 160 | 33 |
| Carvedilol | Carvedilol | 153 | 36 |
| Losartan Potassium | Losartan Potassium | 152 | 41 |
| Simvastatin | Simvastatin | 145 | 33 |
| Valsartan | Valsartan | 137 | 30 |
| Januvia | Sitagliptin Phosphate | 132 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 24 |
| Alprazolam | Alprazolam | 118 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 117 | 15 |
| Finasteride | Finasteride | 108 | 22 |
| Jardiance | Empagliflozin | 108 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 23 |
| Ozempic | Semaglutide | 100 | 18 |
| Buspirone Hcl | Buspirone Hcl | 96 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 21 |
| Spironolactone | Spironolactone | 88 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 25 |
| Tramadol Hcl | Tramadol Hcl | 86 | 19 |
| Alendronate Sodium | Alendronate Sodium | 76 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 70 | 30 |
| Amoxicillin | Amoxicillin | 68 | 54 |
| Terbinafine Hcl | Terbinafine Hcl | 66 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 64 | 16 |
| Naproxen | Naproxen | 64 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | suppressed |
| Piroxicam | Piroxicam | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 11 |
| Meclizine Hcl | Meclizine Hcl | 57 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 16 |
| Allopurinol | Allopurinol | 55 | 11 |
| Sertraline Hcl | Sertraline Hcl | 55 | 13 |
| Estradiol | Estradiol | 54 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Azithromycin | Azithromycin | 46 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 43 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 32 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 33 |
| Famotidine | Famotidine | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Latanoprost | Latanoprost | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 32 |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Lactulose | Lactulose | 26 | 14 |
| Brilinta | Ticagrelor | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 21 | 19 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 14 |
| Prednisone | Prednisone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $251.30 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, ELIQUIS, EVENITY, FARXIGA, NURTEC ODT, PROLIA, REXULTI | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error